C-OCOTAKL Therapeutics
plant-derived metabolites, NF-kB/Nrf2 modulation, senotherapeutics
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-OCOT
C-OCOTC-OCOTplant-derived metabolites, NF-kB/Nrf2 modulation, senotherapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
AKL Therapeutics plant-derived metabolites, NF-kB/Nrf2 modulation, senotherapeutics
AKL Therapeutics is a privately held pharmaceutical company developing treatments for inflammatory diseases with high unmet need. Its lead clinical asset is APPA, a patented investigational oral medicine for osteoarthritis and other diseases of ageing. The company says APPA combines two synthetically produced isomers and modulates NF-kB and Nrf2 activity rather than blocking immune response.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
AKL Therapeutics — Translational · Lower middle. Derived deterministically from 2 extracted project(s). Most-advanced status: phase 2. Band: translational. Modifiers: +5 modality breadth (3 modalities…
Source: Deterministic